ReviewMedical oncology (Northwood, London, England)2016
Metabolomics in pancreatic cancer biomarkers research.
Review in Medical oncology (Northwood, London, England), 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- Advances in the Detection of Pancreatic Cancer Through Liquid Biopsy.Frontiers in oncology · 2021Pooled it
- A systematic review on metabolomics-based diagnostic biomarker discovery and validation in pancreatic cancer.Metabolomics : Official journal of the Metabolomic Society · 2018Pooled it
- Metabolomics study of the effects of zinc sulfate in minimal hepatic encephalopathy.Scientific reports · 2026Article
- Development of a metabolite calculator for diagnosis of pancreatic cancer.Cancer medicine · 2023Article
- Prediction of Pathologic Change Development in the Pancreas Associated with Diabetes Mellitus Assessed by NMR Metabolomics.Journal of proteome research · 2023Article
- Article
- The interaction of ammonia and manganese in abnormal metabolism of minimal hepatic encephalopathy: A comparison metabolomics study.PloS one · 2023Article
- Progress on diagnostic and prognostic markers of pancreatic cancer.Oncology research · 2023Review
- Multivariate Analysis of RNA Chemistry Marks Uncovers Epitranscriptomics-Based Biomarker Signature for Adult Diffuse Glioma Diagnostics.Analytical chemistry · 2022Article
- Integrative analysis of metabolome and gut microbiota in Patients with pancreatic ductal adenocarcinoma.Journal of Cancer · 2022Article
- Potential Metabolite Biomarkers for Early Detection of Stage-I Pancreatic Ductal Adenocarcinoma.Frontiers in oncology · 2021Article
- Accurate quantification of urinary metabolites for predictive models manifest clinicopathology of renal cell carcinoma.Cancer science · 2020Article
- Relationships between plasma lipidomic profiles and brown adipose tissue density in humans.International journal of obesity (2005) · 2020Article
- A Prospective Targeted Serum Metabolomics Study of Pancreatic Cancer in Postmenopausal Women.Cancer prevention research (Philadelphia, Pa.) · 2019Article
- Exosomes as critical mediators of cell-to-cell communication in cancer pathogenesis and their potential clinical application.Translational cancer research · 2019Review
- Metabolomic Study on Nude Mice Models of Gastric Cancer Treated with Modified Si Jun Zi Tang via HILIC UHPLC-Q-TOF/MS Analysis.Evidence-based complementary and alternative medicine : eCAM · 2019Article
- Exploring a Novel Screening Method for Patients with Oral Squamous Cell Carcinoma: A plasma Metabolomics Analysis.The Kobe journal of medical sciences · 2018Article
- Effect of storage conditions on salivary polyamines quantified via liquid chromatography-mass spectrometry.Scientific reports · 2018Article
- Jumonji AT-rich interactive domain 1B promotes the growth of pancreatic tumors via the phosphatase and tensin homolog/protein kinase B signaling pathway.Oncology letters · 2018Article
- Simultaneous quantification of serum monounsaturated and polyunsaturated phosphatidylcholines as potential biomarkers for diagnosing non-small cell lung cancer.Scientific reports · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Pancreatic cancer is one of the worst prognoses of all malignancies. More than 40,000 deaths a year from this disease are observed in European Union alone. The only possibly curative treatment of pancreatic cancer is surgery, yet only 15-20% of patients have operable disease and even patients, which go through surgery and adjuvant chemotherapy, survival is less than 30%. The sensitive and specific biomarkers which could be used for the advance of early diagnostics are needed and constantly researched. Metabolomics is a technology which analyzes the concentrations of low-molecular-weight metabolites (the metabolome) has lately effectively developed due to the improvements in analytical technology. Metabolome analysis can be a one of the useful approaches for the biomarker discovery and disease diagnosis. Here we discuss recent discoveries in the field of pancreatic cancer metabolomics as well as the most promising biomarkers for diagnostics, prognosis and prediction.
Indexed as
Identifiers
27807722What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.